Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 20.

Order by Relevance | Date

Total 7090 results found since Jan 2013.

Primary adrenal non-Hodgkin lymphoma: a case report and review of the literature
ConclusionsPrimary adrenal lymphoma is an extremely rare but rapidly progressive disease. It generally carries a poor prognosis, partly because an optimal treatment protocol has not yet been established. Further studies with larger sample sizes are needed to establish the best treatment option and increase overall survival.
Source: Journal of Medical Case Reports - April 15, 2017 Category: Journals (General) Source Type: research

Acute hepatitis B virus infection with delayed appearance of hepatitis B core antibody in an immunocompromised patient: a case report
ConclusionsWhen confronted with positive hepatitis B surface antigen in the absence of hepatitis B core  antibody, consideration should be given to the possibility of both acute and persistent infection particularly in the setting of immunosuppression so that appropriate clinical management and public health interventions can take place. Given the increasing use of biologicals such as anti-tumor necr osis factor therapies either alone or with other immunosuppressive agents, this phenomenon may be encountered more frequently.
Source: Journal of Medical Case Reports - April 17, 2017 Category: Journals (General) Source Type: research

Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report
ConclusionsCastleman disease has a broad spectrum of clinical manifestations, disease pathogeneses, and associations and/or complications. Medical professionals need to be familiar with this spectrum because timely diagnosis and aggressive targeted therapy are the cornerstones of managing these patients.
Source: Journal of Medical Case Reports - May 14, 2017 Category: General Medicine Source Type: research

In Lymphoma, Best Partner With Rituximab Still in Question In Lymphoma, Best Partner With Rituximab Still in Question
Results from the StiL and BRIGHT studies confirm the long-term benefits of rituximab, but the optimal chemotherapy partner is still in question.Medscape Medical News
Source: Medscape Medical News Headlines - June 15, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Medical News Today: Human antibody bolsters cancer drug performance
Some patients do not respond to the cancer drug rituximab, but breaking research finds that the addition of a human antibody reduces this resistance.
Source: Health News from Medical News Today - July 1, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Rituximab Biosimilars Shown to Be Safe and Effective Rituximab Biosimilars Shown to Be Safe and Effective
Two randomized trials confirm that two new biosimilars that have recently been introduced in Europe are efficacious and comparable to the reference product. Other biosimilars are on the way.Medscape Medical News
Source: Medscape Medical News Headlines - July 28, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Primary Hepatic Lymphoma Mimicking Cholangiocarcinoma.
We present the case of a 67-year-old male with no significant medical history presented with abdominal pain, jaundice, fever, and abnormal liver function tests. Abdominal sonography and computed tomography scan suggested a diagnosis of obstructive jaundice and cholangitis due to cholangiocarcinoma (Klatskin tumor). A subsequent liver biopsy diagnosed PHL, and the patient was treated with combination chemotherapy, including rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). PHL should be considered in patients presenting with biliary obstruction. PMID: 28804587 [PubMed]
Source: Oman Medical Journal - August 16, 2017 Category: Middle East Health Tags: Oman Med J Source Type: research

MENTOR Results, New Trial Design Pitches at Kidney Week MENTOR Results, New Trial Design Pitches at Kidney Week
Findings from a randomized comparison of rituximab and cyclosporine for membranous nephropathy will be released here at Kidney Week, along with innovative trial design ideas for the future.Medscape Medical News
Source: Medscape Medical News Headlines - October 25, 2017 Category: Consumer Health News Tags: Nephrology News Source Type: news

Success of anti-CD20 monoclonal antibody treatment for severe autoimmune hemolytic anemia caused by warm-reactive immunoglobulin A, immunoglobulin G, and immunoglobulin M autoantibodies in a child: a case report
ConclusionsThe case that we report in this paper shows that rituximab could be an alternative therapeutic option in severe acute autoimmune hemolytic anemia with profound hemolysis refractory to conventional treatment. Moreover, it may preclude the use of plasmapheresis in such an urgent situation with a sustained remission.
Source: Journal of Medical Case Reports - November 14, 2017 Category: General Medicine Source Type: research

Venetoclax and Rituximab: New Standard of Care in CLL? Venetoclax and Rituximab: New Standard of Care in CLL?
The new combination of venetoclax and rituximab was superior to the standard-of-care combination of bendamustine and rituximab in the treatment of relapsed/refractory CLL.Medscape Medical News
Source: Medscape Medical News Headlines - December 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Clinical Problem Solving: A Tobacco Merchant Who Can't Spit.
Authors: Benizri S, Agmon-Levin N, Kitrey ND, Carter D, Goshen E, Sharabi Y Abstract BACKGROUND: A 47 year old man presented with a combination of dry mouth and lightheadedness while standing. His medical background was unremarkable except for cigarette smoking and hyperlipidemia. Sjögren's syndrome was ruled out, and he was referred for evaluation of orthostatic hypotension, which by then included syncopal episodes and injuries. Additional symptoms included dry eyes, constipation, reduced sweating, and erectile dysfunction. After excluding medications and structural cardiac abnormalities as causes of orthostatic ...
Source: The Israel Medical Association Journal - December 14, 2017 Category: General Medicine Tags: Isr Med Assoc J Source Type: research

Rituximab Outperforms Other Drugs in RRMS Rituximab Outperforms Other Drugs in RRMS
In a new study, rituximab was superior to other drugs -- including fingolimod, natalizumab, and dimethyl fumarate -- in efficacy, safety, and tolerability in patients with relapsing-remitting MS.Medscape Medical News
Source: Medscape Medical News Headlines - January 11, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Recovery of hepatitis C specific T ‐cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis
Journal of Medical Virology, EarlyView.
Source: Journal of Medical Virology - January 4, 2018 Category: Virology Source Type: research

Combo Improves Outcomes in Waldenstrom ' s Macroglobulinema Combo Improves Outcomes in Waldenstrom ' s Macroglobulinema
The combination of ibrutinib plus rituximab dramatically extends progression-free survival over rituximab alone, regardless of treatment or mutational status.Medscape Medical News
Source: Medscape Medical News Headlines - June 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Idelalisib in a patient with refractory Waldenstr öm’s macroglobulinemia complicated by anuric renal failure: a case report
ConclusionOur patient ’s case provides the first evidence, to the best of our knowledge, that idelalisib may be an efficient treatment option for patients with Waldenström’s macroglobulinemia complicated by anuric renal failure and in whom ibrutinib is contraindicated.
Source: Journal of Medical Case Reports - June 12, 2018 Category: General Medicine Source Type: research